Mahana Therapeutics, developer of prescription digital therapeutics designed to empower sufferers with power situations to reside fuller lives, has signed an settlement with the Shopper Well being division of Bayer, which can see its new digital therapeutics commercialised.
The partnership will deliver collectively the experience Mahana has in digital therapeutic growth with Bayer’s intention to ship merchandise to assist individuals take larger management of their very own well being by way of using digital options.
Earlier this 12 months Bayer introduced the launch of a brand new enterprise unit. The Shopper Well being division is targeted on bringing new digitally-enabled precision well being merchandise to market. The division is prioritising the event of merchandise that may allow individuals to make use of digital options to take management of their well being, and facilitate their capacity to make knowledgeable decisions based mostly on private insights and novel supply mechanisms.
David Evendon-Challis, head of R&D and chief scientific officer for the Shopper Well being division of Bayer, stated: “Digital therapeutics are an ideal addition to our portfolio of care and faucet into new tech-savvy customers searching for drug-free therapies in addition to assist remove gaps in care provision. We’re excited to associate with Mahana Therapeutics and enter the sector of digital therapeutics in shopper well being.”
The primary product from Mahana Therapeutics was Mahana IBS which offers cognitive remedy to adults with the situation. The product was the primary digital therapeutic to obtain FDA clearance for the therapy of IBS.
Simon Levy, CEO of Mahana, stated: “This historic partnership is among the many first main investments ever made by a world life sciences firm into the rising market for digital therapeutics.
“Via this settlement, we will additional broaden the supply of our modern prescription digital therapeutics for sufferers and their caregivers world wide who search efficient therapy for power situations.”